Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Comparative effectiveness of oral antidiabetic drugs in preventing cardiovascular mortality and morbidity: A network meta-analysis.

Lee G, Oh SW, Hwang SS, Yoon JW, Kang S, Joh HK, Kwon H, Kim J, Park D.

PLoS One. 2017 May 25;12(5):e0177646. doi: 10.1371/journal.pone.0177646. eCollection 2017.

3.

Efficacy and safety of thiazolidinediones in diabetes patients with renal impairment: a systematic review and meta-analysis.

Wang W, Zhou X, Kwong JSW, Li L, Li Y, Sun X.

Sci Rep. 2017 May 11;7(1):1717. doi: 10.1038/s41598-017-01965-0.

4.

Treatment of Dyslipidemias to Prevent Cardiovascular Disease in Patients with Type 2 Diabetes.

Khavandi M, Duarte F, Ginsberg HN, Reyes-Soffer G.

Curr Cardiol Rep. 2017 Jan;19(1):7. doi: 10.1007/s11886-017-0818-1. Review.

5.

The effect of pioglitazone on circulating interleukin-10 and tumor necrosis factor-alpha levels in a patient with metabolic syndrome: A randomized, double-blind controlled trial.

Pourmoghaddas A, Dormiani-Tabatabaei M, Sadeghi M, Kermani-Alghoraishi M, Golshahi J, Shokouh P.

ARYA Atheroscler. 2015 Jan;11(1):36-42.

6.

Geraniol, alone and in combination with pioglitazone, ameliorates fructose-induced metabolic syndrome in rats via the modulation of both inflammatory and oxidative stress status.

Ibrahim SM, El-Denshary ES, Abdallah DM.

PLoS One. 2015 Feb 13;10(2):e0117516. doi: 10.1371/journal.pone.0117516. eCollection 2015.

7.

Cardiovascular safety profile of currently available diabetic drugs.

Azimova K, San Juan Z, Mukherjee D.

Ochsner J. 2014 Winter;14(4):616-32. Review.

8.

Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.

Soccio RE, Chen ER, Lazar MA.

Cell Metab. 2014 Oct 7;20(4):573-91. doi: 10.1016/j.cmet.2014.08.005. Epub 2014 Sep 18. Review.

9.

Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes.

Nwose OM, Jones MR.

Clin Med Insights Endocrinol Diabetes. 2013 Dec 8;6:75-9. doi: 10.4137/CMED.S12590. Review.

10.

Short-term continuous subcutaneous insulin infusion combined with insulin sensitizers rosiglitazone, metformin, or antioxidant α-lipoic acid in patients with newly diagnosed type 2 diabetes mellitus.

Huang Z, Wan X, Liu J, Deng W, Chen A, Liu L, Liu J, Wei G, Li H, Fang D, Li Y.

Diabetes Technol Ther. 2013 Oct;15(10):859-69. doi: 10.1089/dia.2013.0013. Epub 2013 Aug 30.

11.

Diabetes: glycaemic control in type 2 (drug treatments).

Gorter KJ, van de Laar FA, Janssen PG, Houweling ST, Rutten GE.

BMJ Clin Evid. 2012 Oct 11;2012. pii: 0609. Review.

12.

Effects of Pioglitazone on Asymmetric Dimethylarginine and Components of the Metabolic Syndrome in Nondiabetic Patients (EPICAMP Study): A Double-Blind, Randomized Clinical Trial.

Shokouh P, Joharimoghadam A, Roohafza H, Sadeghi M, Golabchi A, Boshtam M, Sarrafzadegan N.

PPAR Res. 2013;2013:358074. doi: 10.1155/2013/358074. Epub 2013 Apr 18.

13.

Influence of pioglitazone on experimental heart failure and hyperlipidemia in rats.

Biswas A, Rabbani SI, Devi K.

Indian J Pharmacol. 2012 May;44(3):333-9. doi: 10.4103/0253-7613.96305.

14.

Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.

Deehan R, Maerz-Weiss P, Catlett NL, Steiner G, Wong B, Wright MB, Blander G, Elliston KO, Ladd W, Bobadilla M, Mizrahi J, Haefliger C, Edgar A.

PLoS One. 2012;7(4):e35012. doi: 10.1371/journal.pone.0035012. Epub 2012 Apr 13.

16.

Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.

Chaudhuri A, Rosenstock J, DiGenio A, Meneghini L, Hollander P, McGill JB, Dandona P, Ilgenfritz J, Riddle M.

Diabetes Metab Res Rev. 2012 Mar;28(3):258-67. doi: 10.1002/dmrr.1305.

17.

Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes.

Parson HK, Bundy MA, Dublin CB, Boyd AL, Paulson JF, Vinik AI.

Diabetes Metab Syndr Obes. 2010 Jan 25;3:19-26.

18.

Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL.

Millar JS, Ikewaki K, Bloedon LT, Wolfe ML, Szapary PO, Rader DJ.

J Lipid Res. 2011 Jan;52(1):136-42. doi: 10.1194/jlr.P008136. Epub 2010 Oct 22.

19.

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.

Triplitt C, Cersosimo E, DeFronzo RA.

Vasc Health Risk Manag. 2010 Sep 7;6:671-90. Review.

20.

A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy.

Raboud JM, Diong C, Carr A, Grinspoon S, Mulligan K, Sutinen J, Rozenbaum W, Cavalcanti RB, Wand H, Costagliola D, Walmsley S; Glitazone and Lipoatrophy Meta-Analysis Working Group.

HIV Clin Trials. 2010 Jan-Feb;11(1):39-50. doi: 10.1310/hct1101-39.

Supplemental Content

Support Center